Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Hassell (OPP1153692; INV-008352): Vaccine Product Development Center |
| Strategy: | Protein & peptide vaccines |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Assays completed |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A randomized, double-blinded, placebo-controlled, dose escalation Phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 vaccine, adjuvanted, in healthy, HIV uninfected adults
Description
CAVD 750 (IAVI W001) is a Phase 1 clinical trial to evaluate the safety and tolerability of intramuscular administration of the adjuvanted HIV envelope protein BG505 SOSIP.664 gp140 vaccine.
Sign in to see full information about this study and to download study data.
Products
AS01B BG505 SOSIP.664 Tris-NaCl DiluentIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.